Citations

Clear

16280 citation(s) found for "Yu, David".

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma
Usmani, Saad, Bories, Pierre, Gasparetto, Cristina, Dingli, David, Lonial, Sagar, Siegel, David, Yee, Andrew, Varga, Cindy, Trudel, Suzanne, Dachs, Laura Rosiñol, Rodriguez-Otero, Paula, Manier, Salomon, Berdeja, Jesús, Afrough, Aimaz, Baker, Warren, Hasheminasab, Seyed Alireza, Thakurta, Anjan, Sridharan, Vinidhra, Flynt, Erin, Barnett, Miriam, Versmee, Laura, Mateos, María-Victoria, Touzeau, Cyrille, Chung, Alfred, Roy, Vivek, Stadtmauer, Edward, Usmani, Saad, Bories, Pierre, Gasparetto, Cristina, Dingli, David, Lonial, Sagar, Siegel, David, Yee, Andrew, Varga, Cindy, Trudel, Suzanne, Dachs, Laura Rosiñol, Rodríguez‐Otero, Paula , Manier, Salomon, Berdeja, Jesús, Afrough, Aimaz, Baker, Warren, Hasheminasab, Seyed Alireza, Thakurta, Anjan, Sridharan, Vinidhra, Flynt, Erin, Barnett, Miriam, Versmee, Laura, Mateos, María-Victoria, Touzeau, Cyrille, Chung, Alfred, Roy, Vivek, Stadtmauer, Edward

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 250-250

10.1182/blood-2025-250 Get It

Abstract Background Translocation of chromosomes 4 and 14 (t(4;14)) results in overexpression of MMSET and has been associated with poor clinical outcomes in patients (pts) with multiple myeloma (MM). KTX-1001 is a first-in-class, potent, and selective oral inhibitor of MMSET (also known as NSD2) developed as the first investigational therapy to directly target the high-risk t(4;14) translocation, a key molecular driver in MM. KTX-1001 binds to and inhibits the catalytic SET domain of MMSET, thereby suppressing the deposition of dimethylated histone H3 lysine 36 (H3K36me2), leading to downregulation of oncogenic histone modifications and epigenetic reprogramming of malignant plasma cells. Preclinically, KTX-1001 synergistically inhibited cell viability in MM cell lines when combined with a proteasome inhibitor (PI), immunomodulatory drug (IMiD), or cereblon E3 ligase modulator (CELMoD™). Preliminary findings were previously reported from the initial cohort of 18 pts enrolled in a first-in-human phase 1 trial evaluating KTX-1001 in relapsed/refractory multiple myeloma (RRMM; NCT05651932; Bories et al. Blood. 2024;144[Suppl 1]:3370). Here, we present updated results from this study. Methods RRMM pts who received ≥3 prior therapies, including PI, IMiD and anti-CD38 monoclonal antibody (anti-CD38 mAb), received oral KTX-1001 across 9 dose levels using a 3+3 dose-escalation design. Primary objective was to determine the recommended Phase 2 dose (RP2D) and the maximum tolerated dose (MTD). Secondary objectives included pharmacokinetics, pharmacodynamics (PD), and primary efficacy. The dose expansion phase has been initiated to evaluate KTX-1001 in combination with either carfilzomib or the investigational CELMoD™ mezigdomide in t(4;14) RRMM pts. Results As of 13 June 2025, 40 pts have been treated in the monotherapy dose-escalation phase. The maximum tolerated dose (MTD) was exceeded due to dose-limiting toxicities (DLTs) in 2 pts: two Grade (Gr) 4 thrombocytopenia and one Gr 3 epistaxis. Backfill at selected dose levels is ongoing to further characterize safety profile and refine dose optimization. The median time from initial MM diagnosis was 8 years (range:2-20) with a median of 6.5 prior lines of therapy (range: 3-25). This included stem cell transplant (70%), BCMA CAR-T (42.5%), and non-CAR-T BCMA targeted drugs such as antibody-drug conjugates and bispecific antibodies (57.5%). The median age was69 years (range:50-83); 21 were female and 19 were male. Extra-medullary disease was present in 13 (32.5%) pts. Nineteen (47.5%) pts had t(4;14) translocation, 5 (12.5%) had 1q21 gain and 4 (10%) had deletion 17p. A total of 16 (40%) pts have shown a treatment response according to IMWG criteria or have achieved stable disease: 1 VGPR (10+ months), 1 PR (4+ months), 2 MR (3+ and 12 months), 12 SD (2-20+ months). KTX-1001 has demonstrated a favorable tolerability profile. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 31 (77.5%) pts. The most frequent (≥20% pts) Gr 3/4 TEAEs were thrombocytopenia in 12 pts (30%; grade 4 in 8 [20%]), neutropenia in 12 pts (30%; febrile neutropenia in 2 [5%]), anemia in 10 (25%) pts. Gr 3 infections were observed in 5 (12.5%) pts and fatigue in 5 (10%) pts. The main reason for treatment discontinuation was progressive disease (57.5%), other pts discontinued due to physician decision (5%), consent withdrawal (5%), and one pt due to adverse event. Twelve (30%) pts remain on treatment. At Cycle 1 Day 15, drug exposure and steady-state concentrations of KTX-1001 increased with dose. A dose-dependent reduction in H3K36me2, the primary PD marker of KTX-1001 activity, was observed in peripheral blood at Cycle 2 Day 1 and beyond, which plateaued above dose-level 4. Paired bone marrow samples further confirmed on-target PD effects, with a marked reduction in H3K36me2 levels in MM cells at Cycle 2 Day 1 with observed anti-MM effect of reduced proliferation of MM cells with concomitant increased proliferation in immune cells in pts achieving clinical benefit. ConclusionsKTX-1001 is a novel agent showing tolerable safety profile in RRMM and demonstrating promising single agent activity in heavily pretreated, triple class refractory RRMM including those with high-risk features. KTX is currently evaluated in ongoing study in combination with carfilzomib and the investigational CELMoD™ mezigdomide in t(4;14) RRMM pts.
KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Muffly, Lori, Shah, Bijal, Aldoss, Ibrahim, Muffly, Lori , Muffly, Lori , Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Shah, Bijal, Aldoss, Ibrahim

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3365-3365

10.1182/blood-2025-3365 Get It

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71% of patients (pts) treated in the pivotal ZUMA-3 trial. Patients with B-ALL with high-risk (HR) genetics are known to have inferior outcomes with chemotherapy, but little is known about the influence of HR ALL genetics on responses to chimeric antigen receptor (CAR)-T in adults. In this study, we assessed the impact of HR ALL genetics on outcomes in a large cohort of adult patients treated with brexu-cel for R/R Philadelphia chromosome (Ph)-negative B-ALL. Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database which includes data from 40 U.S. centers. NCCN guidelines (NCCN Guidelines in Oncology, ALL v2.2025) were used to define HR B-ALL genetics; lack of HR genetics was defined as standard-risk (SR). The primary outcome was event-free survival (EFS), defined as lack of response, disease progression, or death from any cause. Secondary outcomes were overall survival (OS), relapse free survival (RFS) and response rates including complete response (CR), CR incomplete count recovery (CRi), measurable residual disease negative CR (MRD-) by flow or NGS and progressive disease (PD). Multivariable models were adjusted for age, pre-infusion blast percentage, prior allo-HCT, and post CAR-T allo-HCT (modeled as a time-varying covariate). Results: The cohort included 286 pts: 169 with HR and 117 with SR B-ALL. The HR cohort included TP53m (n=24, 14%), KMT2Ar (n=16, 9%), CRLF2r (n=65, 39%) and other HR genetics such as JAK2 and other Ph-like, IKZF1, complex cytogenetics (n=64, 38%). Relative to SR pts, HR pts were more commonly Hispanic (50% vs 28%). HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), prior blinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). The presence of CNS disease (11% HR vs 12% SR) and extramedullary disease (EMD, 22% HR vs 29% SR) at apheresis was also similar. CR/CRi was achieved in 90.5% of evaluable HR pts (n=147) and 90.2% of evaluable SR pts (n=102); MRD- rates were also similar between HR and SR pts at 78.9% and 78.2% respectively. In unadjusted analyses, EFS did not significantly differ between HR pts (median 9.6 mos; 1-yr: 46%, 95% CI 38%-54%) and SR pts (median 11.6 mos; 1-yr: 48%, 95% CI 38%- 58%). Median RFS (HR: 12.2 mos, SR: 13.3 mos) and median OS (HR: 22.4 mos, SR: 21.0 mos) were also similar. Multivariable models demonstrated no significant associations between HR B-ALL and EFS (HR 1.09, 95% CI 0.73-1.63), RFS (HR 1.13, 95% CI 0.71-1.80), or OS (HR 0.96, 95% CI 0.62- 1.48) relative to SR ALL. 28% of HR patients and 21% of SR patients underwent consolidative allo-HCT. Among the HR subgroup, CR/CRi rate was lowest in KMT2Ar (71%) relative to TP53m (95%), CRLF2r (95%), and other HR genetics (89%). The median EFS was lowest in KMT2Ar (4.1 mos), followed by TP53m (6.9 mos), CRLF2r (11.6 mos), and other HR (11.1 mos). Median OS was also lowest in KMT2Ar (6.8 mos) vs 22.4 mos in TP53m and not reached in CRLF2r or other HR. PD was highest in KMT2Ar pts (29%), as compared to 11% HR other, 10% SR, and 5% TP53 and CRLF2r. The rate of relapse among those that achieved CR across the groups was similar and ranged between 28% -40%. Rates of CD19 negative relapse were similar between all subgroups (13%-15%), however 21% of KMT2A pts underwent myeloid transformation as compared 0% for TP53 and CRLF2 pts, and 2% among other HR and SR pts. 25% of KMT2Ar patients underwent consolidative allo-HCT as compared to 32% CRLF2 pts, 29% TP53 pts, 25% other HR pts and 21% SR pts. Multivariable models evaluating the different genomic subgroups demonstrated that relative to SR B-ALL, only KMT2Ar was associated with inferior OS (HR 3.17, 95% CI 1.53-6.58, p=0020). No associations were seen between HR subgroups and EFS. Conclusion: To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-T assessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts with KMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloid transformation at relapse, suggesting that alternative strategies are necessary to improve outcomes for patients with R/R KMT2Ar B-ALL.
Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients
Muchtar, Eli, Geyer, Susan, Dispenzieri, Angela, Grogan, Martha, Kourelis, Taxiarchis, Buadi, Francis, Kapoor, Prashant, Dingli, David, Gonsalves, Wilson, Leung, Nelson, Merlini, Giampaolo, Rosenthal, Julie, Lyle, Melissa, Hayman, Suzanne, Lacy, Martha, Siddiqui, Mustaqeem, Cook, Joselle, Abdallah, Nadine, Binder, Moritz, Zanwar, Saurabh, Lin, Yi, Warsame, Rahma, Kyle, Robert, Rajkumar, S. Vincent, Kumar, Shaji, Gertz, Morie, Muchtar, Eli, Geyer, Susan, Dispenzieri, Angela, Grogan, Martha, Kourelis, Taxiarchis, Buadi, Francis, Kapoor, Prashant, Dingli, David, Gonsalves, Wilson, Leung, Nelson, Merlini, Giampaolo, Rosenthal, Julie, Lyle, Melissa, Hayman, Suzanne, Lacy, Martha, Siddiqui, Mustaqeem, Cook, Joselle, Abdallah, Nadine, Binder, Moritz, Zanwar, Saurabh, Lin, Yi, Warsame, Rahma, Kyle, Robert, Rajkumar, S. Vincent, Kumar, Shaji, Gertz, Morie

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3960-3960

10.1182/blood-2025-3960 Get It

Abstract Cardiac involvement in AL amyloidosis significantly impacts both short and long-term survival. Achieving cardiac complete response (CarCR) is linked to excellent survival, comparable to that of the general population. We undertook this study to characterize patients with AL amyloidosis who achieved CarCR. Methods: A single-center retrospective study of patients diagnosed with cardiac AL amyloidosis between 2004 and 2023 and achieved a documented CarCR for at least 12 months. Patients were included if they had evidence of cardiac involvement confirmed by cardiac imaging (transthoracic echocardiogram or cardiac magnetic resonance) and Congo red–positive tissue (non-cardiac or heart biopsy), and were evaluable for cardiac response based on baseline NT-proBNP > 650 pg/mL or BNP > 150 pg/mL. CarCR was defined as a reduction in NT-proBNP to less than 350 pg/mL (or BNP less than 80 pg/mL). Heart transplant patients were excluded. Results: Sixty-three patients were included, representing 4.6% of the cardiac evaluable population in the study period. This proportion increased in the second period compared to the first period (7.5% vs 3.2%, P<0.001). The median age at diagnosis of 57 years (ranging from 29 to 79); 63% were male. Lambda light chain disease was evident in 63% of patients. The median difference between the involved and uninvolved light chain (dFLC) at baseline was 429 mg/L (interquartile range [IQR] 143-708). While all patients had cardiac involvement, 63% also presented with extra-cardiac involvement [kidneys (52%), liver (16%), autonomic nerves (14%), luminal gastrointestinal tract (11%), and peripheral nerves (10%)]. The median baseline NT-proBNP for the entire cohort was 1977 pg/mL (IQR 1393-3026). The median troponin T (n=43) was 0.02 ng/mL (IQR <0.01-0.05) and the median high-sensitivity troponin T (n=19) was 49 ng/L (IQR 38-79 ng/L). Cardiac stage distribution, according to the European modification of the Mayo 2004 staging model, was as follows: 59% stage II, 39% stage IIIa, and 2% stage IIIb. At baseline, echocardiogram features included a median left ventricular (LV) ejection fraction of 63%, a median intraventricular septum thickness of 14 mm, and a median average LV longitudinal strain of -12%. The most common first-line therapies were autologous stem cell transplantation (ASCT; with or without induction, 54%), bortezomib-containing therapy (22%), and daratumumab-containing therapy (13%). Hematological complete response rates at 3-month, 6-month, and best response prior to CarCR were 32%, 49% and 76%, respectively. At CarCR, the median NT-proBNP was 265 pg/mL (IQR 220-307) with a median time from treatment onset to CarCR achievement of 20.6 months. At CarCR, 33% of patients were on loop diuretics. The CarCR rate at 6, 12, 24, 36, 48 and 60 months from treatment onset was 10%, 39%, 81%, 90%, 95% and 96%, respectively. Temporary increase of NT-proBNP above 350 pg/mL with return to CarCR was documented in 46% of patients. Echocardiogram parameters also improved significantly at the time of CarCR, with average left ventricular longitudinal strain showing the greatest median improvement in relation to baseline (from -12% to -17%, p<0.001). However, echocardiographic parameters did not fully normalize in all patients. Cardiac progression was seen in 14% of patients, at a median of 7.6 years from the initial time of CarCR. In addition, subsequent clone-directed therapy was given in 44% of patients at a median of 4.6 years from the initial treatment. With a median follow-up of 9.5 years, eight patients (13%) died, 4 due to causes unrelated to AL. We compared the survival of patients who achieved CarCR to the general U.S. population, matching for age, sex, and the year treatment. The observed survival of CarCR patients was similar to that of the general population (p=0.35). Conclusion: Patients with persistent CarCR >12 months in AL amyloidosis are uncommon and demonstrate excellent outcomes. The achievement of hematological CR was required in 3 out of 4 patients reaching a CarCR. Echocardiographic changes of amyloid infiltration may still persist in this highly favorable cohort, indicating that “complete” response refers primarily to functional and prognostic improvement, not necessarily a full restoration to pre-disease cardiac morphology and function. Achieving CarCR is associated with a low risk of cardiac progression, but the need for subsequent clone-directed therapy remains elevated.
Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients
Steinhardt, Max, Muchtar, Eli, Kourelis, Taxiarchis, Warsame, Rahma, Mauermann, Michelle, Buadi, Francis, Dingli, David, Leung, Nelson, Cook, Joselle, Go, Ronald, Hayman, Suzanne, Gonsalves, Wilson, Kapoor, Prashant, Zanwar, Saurabh, Binder, Moritz, Hellou, Tamer, Tan, Melinda, Fonder, Amie, Hobbs, Miriam, Abdallah, Nadine, Lin, Yi, Siddiqui, Mustaqeem, Kyle, Robert, Einsele, Hermann, Rajkumar, S. Vincent, Kumar, Shaji, Kortüm, K. Martin, Gertz, Morie, Dispenzieri, Angela, Mauermann, Michelle L. , Mauermann, Michelle L , Steinhardt, Max, Muchtar, Eli, Kourelis, Taxiarchis, Warsame, Rahma, Buadi, Francis, Dingli, David, Leung, Nelson, Cook, Joselle, Go, Ronald, Hayman, Suzanne, Gonsalves, Wilson, Kapoor, Prashant, Zanwar, Saurabh, Binder, Moritz, Hellou, Tamer, Tan, Melinda, Fonder, Amie, Hobbs, Miriam, Abdallah, Nadine, Lin, Yi, Siddiqui, Mustaqeem, Kyle, Robert, Einsele, Hermann, Rajkumar, S. Vincent, Kumar, Shaji, Kortüm, K. Martin, Gertz, Morie, Dispenzieri, Angela

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3962-3962

10.1182/blood-2025-3962 Get It

Abstract Background: Gastrointestinal (GI) symptoms are frequent in patients (pts) with systemic light chain amyloidosis (AL), yet their clinical significance remains poorly defined. We investigated the role of symptomatic GI involvement in disease burden, survival, and organ-specific outcomes in a large single-center cohort. Methods From 2010–2025, 4,396 AL pts were evaluated at our center; 560 pts (13%) had provider-attributed symptomatic GI AL. Pts with localized AL or positive biopsy without GI symptoms were excluded (n=38). We analyzed relationships between GI symptoms, anatomic/histologic involvement, laboratory parameters, survival, and need for nutritional support using Wilcoxon rank-sum, Chi-square, Kaplan-Meier, and logistic regression tests. Results GI symptoms included early satiety (n=320/57%), diarrhea (n=189/34%), nausea (n=184/33%), abdominal pain (n=148/26%), dysphagia (n=119/21%), vomiting (n=75/13%), GI bleeding (n=74/13%), and heartburn (n=71/13%). Only nausea and GI bleeding were not associated with cardiac (n=366/65%) renal (n=274/49%) or hepatic (n=84/15%) AL, whereas dysphagia, early satiety and heartburn were more frequent with cardiac (all OR=1.7), abdominal pain and diarrhea with hepatic (OR=2 and 1.6, respectively), and vomiting with renal involvement (OR=2; all p<0.04). Autonomic involvement impacted GI symptoms, often without proof of parenchymal GI amyloid. Of the 124 pts with formal autonomic testing, only 44 (35%) had positive GI biopsies as compared to AL GI pts without proven autonomic involvement (240/436, 55%). Pts with autonomic involvement were more symptomatic than pts with positive GI biopsies, suffering more often from dysphagia (29% vs 19%), diarrhea (41% vs 32%), and gastroparesis (34% vs 9%, all p<0.001). We screened changes in body weight, calcium, VitB12, Hb, PO4, and albumin at diagnosis. Of the 175 pts with documented weight loss in this cohort, pts with GI AL lost more weight compared to those with other organ involvement (21% vs 14% of weight, p=0.002), and had lower phosphate (3.7 vs 4.0 mg/dL, p=0.06). In our cohort of pts with GI symptoms, 298 (53%) had a positive GI biopsy. Biopsy-proven anatomic involvement dictated symptoms (all p<0.05): Of the 20 pts with positive esophageal biopsy, dysphagia was present in 45%; only 33% of the pts without an esophageal biopsy had dysphagia. Similar patterns were seen for the 170 pts with a positive gastric biopsy (n=170) in terms of heartburn (21% vs 11%), for the 165 pts with positive small bowel biopsies in terms of abdominal pain (68% vs 32%), and for the 130 pts with positive colon biopsies and diarrhea (46% vs 33%). Specific histopathological patterns were prognostic. Mucosal involvement (n=161) was an independent risk factor for survival compared to submucosal (n=64) and vascular (n=102) involvement throughout the GI tract (HR 1.83; p=0.03). Three-layer GI infiltration was associated with inferior mOS (2.4 vs 5.1 vs 7.8 y for 3 vs 2 vs 1-layer involvement, HR 3.19/1.56/1; p<0.05). Counterintuitively, vascular involvement had the lowest risk of bleeding in all GI anatomic sites (p=0.02). In the colon, only mucosal involvement was associated with a higher risk of bleeding (OR=5; p=0.04). GI involvement in AL pts did not worsen prognosis (mOS 10.0/6.3y, p=0.02), and pts with isolated GI AL (n=74/13%) had an even better survival (55% surviving at 10 y). Cachexia (n=120; mOS 3.5 vs 7.8 y, p<0.001), need for nutritional support (n=36; mOS 0.9 vs 7.0 y, p<0.001), and diarrhea (mOS 5.8 vs 6.9 y, p=0.06) were risk factors for death. In pts with hematologic response (≥PR), bleeding did not recur within 3 y (n=27), but even with response, diarrhea (n=160) persisted in 39%. Resolution was less frequent without hematologic response (persistence in 69%, OR=3.5). Improvement was most often due to treatment of bacterial overgrowth (11/35 pts; 68%) and loperamide (54/59 pts; 91%). Conclusion In AL, meaningful GI involvement is defined by nausea, diarrhea, occurrence of bleeding, and malnutrition. These are primarily associated with mucosal infiltration. GI symptoms can occur in the face of autonomic involvement. While long-term persistence of GI bleeding is rare after serologic response, cachexia and persistent diarrhea drive morbidity, need for nutritional support, and poor survival.
Molecular association with elevated LDH levels in patients with AML
Alkabbani, Oudai, Jabban, Yazan Khair Eldien , He, Rong , Viswanatha, David S., Bessonen, Kurt, Matin, Aasiya , Hogan, William H., Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Begna, Kebede H. , Al‐Kali, Aref , Jabban, Yazan, Greipp, Patricia T. , Jevremović, Dragan , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William, Alkhateeb, Hassan B. , Shah, Meera

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7039-7039

10.1182/blood-2025-7039 Get It

Abstract Prognosis in acute myeloid leukemia (AML) patients is influenced by various factors, most importantly, patient clinical status and cytogenetic/molecular abnormalities. Within those factors, elevated lactate dehydrogenase (LDH) is considered a poor prognostic indicator in AML patients. Our study aims at exploring the different factors associated with elevated LDH and their impact on overall survival (OS). After obtaining IRB approval, we reviewed the charts of 381 AML patients diagnosed at Mayo Clinic, Rochester, between the years of 2016 and 2023. All data was recorded at the time of AML diagnosis. Patients with no cytogenetic and molecular data were excluded from this study. LDH levels were recorded if measured within 10 days of diagnosis and treatment for AML was not yet given. Both risk stratification and response evaluation were done following the 2022 European LeukemiaNet (ELN) guidelines. OS was calculated from the date of AML diagnosis to the date of last follow-up or death. We used BlueSky Statistics V 10.3.4 for statistical analysis. We identified 299 patients (78.4%) who had elevated LDH levels (normal ≤ 222 U/L) at the time of diagnosis with a median of 417 U/L (range, 223-7989). The median age for those patients was 68 years (range, 18-94), with 78 (26.1%) of them having a prior myeloid disease (MDS, MPN, or MDS/MPN) before AML diagnosis. By risk stratification, more than half of the patients had an adverse risk profile (n=171, 57.2%), while 71 (23.7%) and 57 (19.1%) had an intermediate and favorable risk, respectively. Most of those patients had an abnormal karyotype (n=204, 68.7%), with complex karyotype (n=103, 34.7%) being the most common abnormality, followed by monosomy 7 (n=50, 16.8%) and trisomy 8 (n=46, 15.5%). Next-generation sequencing (NGS) was performed on 268 (89.6%) patients with elevated LDH, and the most common mutations were TP53 (n=60, 22.3%), FLT3-ITD (n=59, 21.1%), and NPM1 (n=51, 18.5%). TP53 mutations were more common in patients with normal/low white blood cell count (WBC) in contrast with FLT3 and NPM1, which were the most common mutations in patients with high WBC. After grouping the patients according to their LDH levels (group 1: 223-444 U/L, group 2: 444-666 U/L, group 3: > 666 U/L), we found that FLT3-ITD mutations were more likely to occur at higher LDH levels i.e. groups 2 and 3 (p= 0.002). The majority of patients with elevated LDH (n=262, 87.6%) received therapy following diagnosis, with the most common treatment regimens being a combination of a hypomethylating agent and venetoclax (HMA+VEN) (n=97, 37%) and a (7+3)-based induction therapy (n=77, 29.4%). When comparing patients with elevated LDH (n=299, 78.4%) to patients who had non-elevated LDH (n=82, 21.5%), no difference in both median age at diagnosis and risk stratification was found. We noticed an increase in WBC (median, 7.7 vs. 2.1) (p<0.001) along with an increase in peripheral blasts (median, 28% vs. 7%) (p<0.001) in elevated LDH patients. Among patients with non-elevated LDH, 21% (n=17) had a complex karyotype compared to 34.7% (n=103) in the elevated LDH group (p=0.022). The molecular profile was different between the 2 groups, where the most common mutations in patients with non-elevated LDH were IDH2 (n=19, 25.3%), RUNX1 (n=17, 23%), and DNMT3A (n=16, 21.6%). All patients (n=82, 100%) in the non-elevated LDH group received therapy after diagnosis. There was no difference in terms of treatment regimens used between the 2 groups. Moreover, no statistical difference in remission rates after one line of therapy was found between those groups where non-elevated LDH patients had a 65.9% remission rate compared to the 55.3% remission rate in patients with elevated LDH (p=0.098). Patients with elevated LDH had a shorter OS than patients with non-elevated LDH (9.5 vs. 26.4 months, p=0.0008). However, median OS was similar across the different groups of elevated LDH. Using univariate analysis in our cohort (n=381), age, HSCT, risk stratification, FLT3 mutation, and LDH elevation all had an impact on OS. However, when comparing those variables using multivariate analysis, age and FLT3 mutation lost their significance (p-value of 0.25 and 0.84, respectively).Complex karyotype and FLT3 mutations were more common in patients with elevated LDH. These patients tend to have higher WBC and peripheral blasts. Elevated LDH had a negative impact on patients' OS regardless of patients' risk classification.
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Shah, Urvi A. , Cogrossi, Laura Lucia , Garcés, Juan‐José , Policastro, Anna , Castro, Francesca , Derkach, Andriy , Fei, Teng , DeWolf, Susan , Grioni, Matteo , Sisti, Sofia , Blaslov, Jenna , Adintori, Peter , McAvoy, Devin , Baichoo, Mirae , Paredes, Jenny , Anuraj, Aishwarya , Pohl, Charlotte , Zinsmeyer, Victoria , Gipson, Brianna , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Block, Torin , Korde, Neha , Tan, Carlyn , Hultcrantz, Malin , Hassoun, Hani , Scordo, Michael , Lahoud, Oscar , Landau, Heather , Peled, Jonathan U. , Chesi, Marta , Mailankody, Sham , D’Souza, Anita , Iyengar, Neil M. , Adintori, Peter A , Hosszu, Kinga K , McAvoy, Devin , Baichoo, Mirae , Cross, Justin R , Paredes, Jenny , Anuraj, Aishwarya , Raj, Sandeep S , Pohl, Charlotte , Zordan, Paola , Zinsmeyer, Victoria , Jesus Faustino Ramos, Ruben J , Lorenzoni, Marco , Gipson, Brianna , Maclachlan, Kylee , Gradissimo, Ana , Boiocchi, Leonardo , Aleynick, Nathan , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Koche, Richard P , Chaligne, Ronan , Block, Torin , Korde, Neha , Tan, Carlyn R , Hultcrantz, Malin , Hassoun, Hani , Shah, Gunjan L , Scordo, Michael , Lahoud, Oscar B , Chung, David J , Landau, Heather , Peled, Jonathan U , Clementi, Nicola , Chesi, Marta , Bergsagel, P. Leif , Mailankody, Sham , Pollak, Michael N , D'Souza, Anita , Landgren, C Ola , Chimonas, Susan , Giralt, Sergio , Usmani, Saad , Iyengar, Neil M , Lesokhin, Alexander M , van den Brink, Marcel R M , Bellone, Matteo , Shah, Urvi A , Derkach, Andriy , Garces, Juan-Jose , Fei, Teng , Maclachlan, Kylee , Aleynick, Nathan , Shah, Gunjan L. , Bergsagel, P. Leif , Pollak, Michaël , Landgren, Ola , Giralt, Sergio , Usmani, Saad Z. , Lesokhin, Alexander M. , Bellone, Matteo

Mayo Clinic

Cancer Discovery | December 4, 2025 | Volume: 16 | Issue: 4 | Pages: 697-720

10.1158/2159-8290.cd-25-1101 | PMID 41342739 Get It

Abstract Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction. See related commentary by Fairfield and Reagan, p. 623
Intravascular Lipoma
Brown, Parker J. , Melville, David M. , Wyse, Aaron , Melville, David

Mayo Clinic

Seminars in Musculoskeletal Radiology | December 3, 2025 | Volume: 29 | Issue: 06 | Pages: 959-962

10.1055/s-0045-1810112 | PMID 41338215 Get It

Intravascular lipomas are rare benign tumors composed of adipose tissue that originate from the walls of blood vessels. They most commonly arise from veins, are typically asymptomatic, and rarely occur in the lower extremities. When large, these tumors can cause symptoms related to venous obstruction, such as swelling and pain. We report a case of a 75-year-old man with an intravascular lipoma in the right common femoral vein, identified during evaluation of lower extremity swelling and poorly healing ulcers. Surgical resection was ultimately required. This case contributes to the few published reports of pathologically proven symptomatic intravascular lipomas involving the lower extremity veins. Comprehensive preoperative imaging played a critical role in characterizing the lesion. The case facilitates a discussion of key differential diagnoses, such as atypical lipomatous tumors/well-differentiated liposarcoma and leiomyosarcoma.
Ultrasound Based Viscoelasticity Imaging Tool for Differentiation of Breast Lesions *
Lundstrom, Julie A., Krumholz, Elias W., Hedin, Daniel , Rosen, David , Lundstrom, Julie A., Krumholz, Elias W., Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

2025 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) | December 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/embc58623.2025.11254647 | PMID 41337349 Get It

Delayed aneurysm rupture after flow-diverter deployment in unruptured aneurysms: a systematic review and meta-analysis
Rodriguez‐Erazú, Fernanda , Ghozy, Sherief , Gutierrez‐Aguirre, Salvador F. , Lara-Velazquez, Montserrat , Cortese, Jonathan , Douri, Dani, Toledo, Otavio F. De , Patel, Milin , Sriraman, Sheetal , Sauvageau, Eric , Kallmes, David F, Ghozy, Sherief , Gutierrez-Aguirre, Salvador F , Lara-Velazquez, Montserrat , Cortese, Jonathan , De Toledo, Otavio Frederico , Aghaebrahim, Amin , Sauvageau, Eric , Hanel, Ricardo A , Hamouda, Abdelrahman M. , Sriraman, Sri, Kallmes, David F. , Hanel, Ricardó A.

Mayo Clinic

Journal of NeuroInterventional Surgery | December 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnis-2025-024135

10.1136/jnis-2025-024135 | PMID 41339075 Get It

Background Delayed aneurysm rupture (DAR) is a potentially devastating complication after flow-diverters (FD) deployment and their exact mechanisms are still unclear. The purpose of this meta-analysis is to synthesize the latest evidence on DAR after FD treatment and identify predictive factors. Methods A systematic review and meta-analysis were conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web of Science, and Embase databases up to June 2024 using variations of “aneurysm “and “delayed aneurysm rupture” terms. Original studies reporting DAR and including more than five patients were included. All analyses were conducted in R software (version 4.4.2), employing the “meta” and “tableone” packages. Results 64 studies with 9820 patients were included, large aneurysm size (OR=1.08, 95% CI (1.02, 1.14), P value=0.008), intra-aneurysmal thrombus (OR=1.05, 95% CI (1.01, 1.09), P value=0.010) and posterior circulation location (OR=1.02, 95% CI (1.00, 1.04), P value=0.014) were significant risk factors for DAR. The pooled prevalence of DAR was 1.40%, with a rate of 1.18% after removing outliers. DAR occurred within 30 days in 66.7% of cases, with a mortality rate of 73.3% at discharge. Conclusion DAR following flow diversion treatment is an uncommon but devastating complication and remains a limitation of the technique. It is influenced by factors such as large aneurysm size, intra-aneurysmal thrombosis, and posterior circulation involvement. The first 30 days post-procedure represent a particularly high-risk period. Despite advancements in FD technology, significant gaps remain, highlighting the need for further research to improve risk assessment and treatment strategies.
Customer discovery in neurointervention: a practical primer for identifying unmet needs
Rana, Shivam , Winters, Kaitlyn, Thacker, Ron, Kallmes, David F, Siddiqui, Adnan H. , Zaidat, Osama O. , Brinjikji, Waleed , Hassan, Ameer E , Siddiqui, Adnan H , Zaidat, Osama O , Brinjikji, Waleed , Winters, Kaitlyn, Kallmes, Kevin M , Hassan, Ameer E , Kallmes, David F.

Mayo Clinic

Journal of NeuroInterventional Surgery | December 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnis-2025-024474

10.1136/jnis-2025-024474 | PMID 41339076 Get It

Background Advancement in neurointervention is frequently driven by the introduction of new technology and devices that improve procedural efficacy and patient outcomes. For physician-innovators, customer discovery—or the process of directly engaging with end users to explore workflows and associated challenges—offers a structured way to identify meaningful problems and guide early innovation. This primer aims to outline stepwise guidance for conducting customer discovery within neurointervention to characterize key areas of unmet need. Methods We detail stepwise guidance for conducting customer discovery founded on foundational business literature. To illustrate this process, we conducted five interviews with expert neurointerventionalists engaged in clinical innovation. Interview transcripts were reviewed and analyzed to track emerging themes, and responses were synthesized into a neurointerventionalist customer profile. Results Responses from interviewed neurointerventionalists suggested that safer vascular access, tools to support treatment prognostication, and condition-specific device design are unmet areas of need. Moreover, interviews revealed broader concerns about stagnation in device innovation and barriers within regulatory and institutional pathways. Conclusions Structured customer discovery identifies unmet needs that may be overlooked when device development is solely driven by technical breakthroughs or published outcomes. By outlining an actionable framework for customer discovery in neurointervention, we provide a practical model for aligning future innovation with real-world clinical challenges.